Previous 10 | Next 10 |
Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum Outcomes Reinforc...
The shares of medical device makers have come under pressure in morning hours after Texas Governor Greg Abbott encouraged the hospitals to consider postponing certain elective medical procedures to make room for rising COVID-19 patients in the state. The seven-day average of COVID-19 hospital...
Glaukos Corporation (GKOS) Q2 2021 Earnings Conference Call August 5, 2021, 4:30 PM ET Company Participants Chris Lewis - Senior Director, Investor Relations and Corporate Strategy and Development Tom Burns - President and CEO Joe Gilliam - Chief Financial Officer Chris Calcaterra - Chief Ope...
Image source: The Motley Fool. Glaukos Corp (NYSE: GKOS) Q2 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Glaukos Corp (GKOS) Q2 2021 Earnings Call Transcript
Glaukos (NYSE:GKOS): Q2 Non-GAAP EPS of -$0.11 beats by $0.14; GAAP EPS of -$0.38 misses by $0.03. Revenue of $78.1M (+147.5% Y/Y) beats by $6.79M. The company ended the second quarter of 2021 with approximately $428M in cash and cash equivalents, short-term investments and restricted cash. T...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2021. Key highlights in...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the...
Shares of Glaukos (NYSE: GKOS) were sinking 14.7% as of 3:28 p.m. EDT on Tuesday. The decline came after Wells Fargo analyst Larry Biegelsen downgraded the stock to an underweight rating from equal weight. Biegelsen also set a $41 price target for Glaukos, nearly 19% below its c...
Gainers: NeuroBo Pharmaceuticals (NRBO) +50%, NeuroMetrix (NURO) +41%, Immunome (IMNM) +31%, Endo International (ENDP) +21%, PLx Pharma (PLXP) +18%.Losers: Ardelyx (ARDX) -75%, Allied Healthcare Products (AHPI) -22%, NRx Pharmaceuticals (...
Glaukos Corporation (GKOS) has lost ~13.0% in the pre-market after Wells Fargo Securities downgraded the stock to underweight from equal-weight, citing the headwinds to the top-line from the proposed reimbursement cuts to the company’s iStent device.In the proposed rules issu...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...